Bone health in adults with obesity before and after interventions to promote weight loss
- PMID: 39053479
- DOI: 10.1016/S2213-8587(24)00163-3
Bone health in adults with obesity before and after interventions to promote weight loss
Erratum in
-
Correction to Lancet Diabetes Endocrinol 2024; published online July 22. https://doi.org/10.1016/S2213-8587(24)00163-3.Lancet Diabetes Endocrinol. 2024 Sep;12(9):e18. doi: 10.1016/S2213-8587(24)00235-3. Epub 2024 Jul 24. Lancet Diabetes Endocrinol. 2024. PMID: 39067456 No abstract available.
Abstract
Obesity and its associated comorbidities constitute a serious and growing public health burden. Fractures affect a substantial proportion of people with obesity and result from reduced bone strength relative to increased mechanical loading, together with an increased risk of falls. Factors contributing to fractures in people with obesity include adverse effects of adipose tissue on bone and muscle and, in many people, the coexistence of type 2 diabetes. Strategies to reduce weight include calorie-restricted diets, exercise, bariatric surgery, and pharmacological interventions with GLP-1 receptor agonists. However, although weight loss in people with obesity has many health benefits, it can also have adverse skeletal effects, with increased bone loss and fracture risk. Priorities for future research include the development of effective approaches to reduce fracture risk in people with obesity and the investigation of the effects of GLP-1 receptor agonists on bone loss resulting from weight reduction.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests JP reports consulting fees from Kyowa Kirin, Eli Lilly, and Theramex; honoraria from Amgen, Besins, CDD Laboratoire de la Femme, Kyowa Kirin, and Theramax; payment for expert testimony from UCB; and support for attending meetings from Kyowa Kirin and Theramax. JEC reports consulting fees from Boehringer-Ingelheim and Alkem; honoraria from Amgen; and payment for expert testimony from Gilead.
Publication types
LinkOut - more resources
Full Text Sources